Cardlytics (NASDAQ:CDLX) Receives Neutral Rating from Bank of America

Cardlytics (NASDAQ:CDLX)‘s stock had its “neutral” rating reaffirmed by investment analysts at Bank of America in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $11.00 price objective on the stock. Bank of America‘s price objective points to a potential upside of 34.06% from the company’s current price.

Several other research analysts have also issued reports on the stock. Northland Securities initiated coverage on shares of Cardlytics in a research note on Tuesday. They issued an “outperform” rating and a $14.00 target price on the stock. Northland Capmk raised shares of Cardlytics to a “strong-buy” rating in a research note on Tuesday. Craig Hallum dropped their target price on shares of Cardlytics from $18.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, May 9th. Lake Street Capital raised their price target on Cardlytics from $13.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, March 15th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $12.00 price objective on shares of Cardlytics in a report on Tuesday, June 11th. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $12.67.

Cardlytics Stock Down 0.4 %

NASDAQ:CDLX opened at $8.21 on Thursday. The company has a market cap of $400.24 million, a price-to-earnings ratio of -1.86 and a beta of 1.67. The company has a debt-to-equity ratio of 1.30, a quick ratio of 2.13 and a current ratio of 2.13. The stock’s fifty day moving average price is $10.64 and its two-hundred day moving average price is $9.57. Cardlytics has a 52-week low of $5.53 and a 52-week high of $20.52.

Cardlytics (NASDAQ:CDLX) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.35) earnings per share (EPS) for the quarter. The firm had revenue of $67.61 million for the quarter. Cardlytics had a negative net margin of 55.23% and a negative return on equity of 25.36%.

Insider Activity at Cardlytics

In other Cardlytics news, CEO Karim Saad Temsamani sold 43,129 shares of the stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $8.65, for a total transaction of $373,065.85. Following the transaction, the chief executive officer now owns 385,530 shares in the company, valued at approximately $3,334,834.50. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Cardlytics news, CEO Karim Saad Temsamani sold 43,129 shares of the firm’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $8.65, for a total value of $373,065.85. Following the sale, the chief executive officer now owns 385,530 shares in the company, valued at $3,334,834.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Amit Gupta sold 23,416 shares of the business’s stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $11.91, for a total value of $278,884.56. Following the sale, the chief operating officer now owns 122,676 shares in the company, valued at $1,461,071.16. The disclosure for this sale can be found here. In the last three months, insiders sold 79,435 shares of company stock worth $828,269. 4.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in shares of Cardlytics by 2.7% in the first quarter. Vanguard Group Inc. now owns 2,211,595 shares of the company’s stock valued at $32,046,000 after purchasing an additional 57,805 shares in the last quarter. Invesco Ltd. boosted its holdings in Cardlytics by 538.1% in the 3rd quarter. Invesco Ltd. now owns 803,241 shares of the company’s stock valued at $13,253,000 after purchasing an additional 677,354 shares during the period. General Equity Holdings LP increased its stake in Cardlytics by 31.0% in the 4th quarter. General Equity Holdings LP now owns 624,058 shares of the company’s stock worth $5,748,000 after acquiring an additional 147,843 shares during the last quarter. LPL Financial LLC increased its position in shares of Cardlytics by 27.5% in the third quarter. LPL Financial LLC now owns 424,150 shares of the company’s stock worth $6,998,000 after purchasing an additional 91,400 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Cardlytics by 12.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 283,086 shares of the company’s stock worth $4,671,000 after buying an additional 32,228 shares during the last quarter. 68.10% of the stock is owned by institutional investors.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.